{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:46:53Z","timestamp":1790621213704,"version":"4.1.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["2016\/R\/14"],"award-info":[{"award-number":["2016\/R\/14"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00635","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:31:54Z","timestamp":1586305914000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Siponimod (BAF312) Activates Nrf2 While Hampering NF\u03baB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration"],"prefix":"10.3389","volume":"11","author":[{"given":"Emanuela","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ottoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianvito","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis.","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01564","article-title":"Immunological aspects of approved MS therapeutics.","volume":"10","author":"Rommer","year":"2019","journal-title":"Front Immunol."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028936","article-title":"Multiple sclerosis pathology.","volume":"8","author":"Lassmann","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis.","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nri2974","article-title":"The outs and the ins of sphingosine-1-phosphate in immunity.","volume":"11","author":"Spiegel","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1212\/WNL.0b013e31820d9507","article-title":"The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.","volume":"76","author":"Soliven","year":"2011","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.","volume":"76","author":"Colombo","year":"2014","journal-title":"Ann Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1212\/WNL.0b013e3182143564","article-title":"Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.","volume":"76","author":"Kowarik","year":"2011","journal-title":"Neurology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000157","article-title":"Myeloid cells as target of fingolimod action in multiple sclerosis.","volume":"2","author":"Di Dario","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1177\/1352458515574895","article-title":"FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.","volume":"21","author":"Luessi","year":"2015","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia.","volume":"256","author":"Noda","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0308-6","article-title":"FTY720 attenuates excitotoxicity and neuroinflammation.","volume":"12","author":"Cipriani","year":"2015","journal-title":"J Neuroinflammation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jns.2013.02.011","article-title":"Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.","volume":"328","author":"Groves","year":"2013","journal-title":"J Neurol Sci."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-41","article-title":"Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation.","volume":"10","author":"Wu","year":"2013","journal-title":"J Neuroinflammation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.2147\/DDDT.S122249","article-title":"Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.","volume":"11","author":"Gajofatto","year":"2017","journal-title":"Drug Des Devel Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1369\/0022155416673969","article-title":"Cell line macroarray: an alternative high-throughput platform to analyze hiPSC Lines.","volume":"64","author":"La Spada","year":"2016","journal-title":"J Histochem Cytochem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1177\/0963689718798564","article-title":"Differentiation of sendai virus-reprogrammed ipsc into beta cells, compared with human pancreatic islets and immortalized beta cell line.","volume":"27","author":"Pellegrini","year":"2018","journal-title":"Cell Transplant."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059252","article-title":"Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling.","volume":"8","author":"Reinhardt","year":"2013","journal-title":"PLoS One."},{"key":"B22","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1073\/pnas.1314085111","article-title":"Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.","volume":"111","author":"Meyer","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1084\/jem.20110698","article-title":"Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration.","volume":"209","author":"Colombo","year":"2012","journal-title":"J Exp Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bph.12207","article-title":"Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.","volume":"169","author":"Healy","year":"2013","journal-title":"Br J Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0494-x","article-title":"The dual S1PR1\/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.","volume":"13","author":"O\u2019Sullivan","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-kappaB signaling in inflammation.","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020184","article-title":"Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release.","volume":"8","author":"Mahmoud","year":"2019","journal-title":"Cells."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.chembiol.2012.07.016","article-title":"A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.","volume":"19","author":"Quancard","year":"2012","journal-title":"Chem Biol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399409001094","article-title":"The Nrf2-ARE cytoprotective pathway in astrocytes.","volume":"11","author":"Vargas","year":"2009","journal-title":"Expert Rev Mol Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis.","volume":"8","author":"Lassmann","year":"2012","journal-title":"Nat Rev Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","article-title":"Astrocytes are active players in cerebral innate immunity.","volume":"28","author":"Farina","year":"2007","journal-title":"Trends Immunol."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020420","article-title":"Astrogliosis.","volume":"7","author":"Sofroniew","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0686-4","article-title":"Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.","volume":"13","author":"Gentile","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023905","article-title":"Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions.","volume":"6","author":"Fischer","year":"2011","journal-title":"PLoS One."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1002\/glia.23058","article-title":"Activation of the astrocytic Nrf2\/ARE system ameliorates the formation of demyelinating lesions in a multiple sclerosis animal model.","volume":"64","author":"Draheim","year":"2016","journal-title":"Glia."},{"key":"B36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00401-013-1183-9","article-title":"Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-kappaB- and STAT1-dependent chemokine production in astrocytes.","volume":"126","author":"Wang","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1471-4159.2009.06190.x","article-title":"Transgenic inhibition of astroglial NF-kappa B leads to increased axonal sparing and sprouting following spinal cord injury.","volume":"110","author":"Brambilla","year":"2009","journal-title":"J Neurochem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1084\/jem.20041918","article-title":"Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury.","volume":"202","author":"Brambilla","year":"2005","journal-title":"J Exp Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.4049\/jimmunol.0802954","article-title":"Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.","volume":"182","author":"Brambilla","year":"2009","journal-title":"J Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection methodology.","volume":"51","author":"Hammad","year":"2010","journal-title":"J Lipid Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/cpdd.424","article-title":"Determination of seminal concentration of fingolimod and fingolimod-phosphate in multiple sclerosis patients receiving chronic treatment with fingolimod.","volume":"7","author":"David","year":"2018","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.107.127183","article-title":"Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.","volume":"323","author":"Foster","year":"2007","journal-title":"J Pharmacol Exp Ther."},{"key":"B44","article-title":"Differentiated pharmacokinetic\/pharmacodynamic (PK\/PD) profiles for Siponimod (BAF312) versus Fingolimod.","volume":"278982","author":"Bigaud","year":"2019","journal-title":"ECTRIMS Online Library."},{"key":"B45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.","volume":"108","author":"Choi","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.173","article-title":"Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.","volume":"5","author":"Mullershausen","year":"2009","journal-title":"Nat Chem Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1474-4422(16)30165-X","article-title":"Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities.","volume":"15","author":"Macrez","year":"2016","journal-title":"Lancet Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1002\/jnr.24029","article-title":"Astroglial glutamate transporters in the brain: regulating neurotransmitter homeostasis and synaptic transmission.","volume":"95","author":"Murphy-Royal","year":"2017","journal-title":"J Neurosci Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/nen.0b013e31812571b0","article-title":"Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage.","volume":"66","author":"Vercellino","year":"2007","journal-title":"J Neuropathol Exp Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/s0165-5728(02)00029-2","article-title":"Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis.","volume":"125","author":"Ohgoh","year":"2002","journal-title":"J Neuroimmunol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171552","article-title":"Fingolimod effects in neuroinflammation: regulation of astroglial glutamate transporters?","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s11064-013-1123-z","article-title":"Reactive oxygen species from human astrocytes induced functional impairment and oxidative damage.","volume":"38","author":"Sheng","year":"2013","journal-title":"Neurochem Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:31:57Z","timestamp":1586305917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2020.00635"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00635","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"article-number":"635"}}